Results 111 to 120 of about 23,127 (334)

In Vivo Imaging of Transplanted Islets with ^(64)Cu-DO3A-VS-Cys^(40)-Exendin-4 by Targeting GLP-1 Receptor [PDF]

open access: yes, 2011
Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on β-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging.
Bading, James R.   +11 more
core   +2 more sources

Lipotoxicity impairs incretin signalling [PDF]

open access: yesDiabetologia, 2012
The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced insulin secretion in response to food ingestion in a glucose-dependent manner. This mechanism forms the basis for incretin-based therapies in type 2 diabetes.
openaire   +2 more sources

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

open access: yesObesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone   +3 more
wiley   +1 more source

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

open access: yesСахарный диабет, 2014
Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ?
Alina Babenko   +4 more
doaj   +1 more source

Glucose metabolism and production of incretins in patients with obesity and type 2 diabetes mellitus after Biliopancreatic bypass surgery in the modification of Hess-Marceau the early stages of postoperative monitoring

open access: yesОжирение и метаболизм, 2015
Introduction: a significant improvement was shown in metabolic control at the early stages after BPD, which was associated with GLP-1 and was regardless of weight loss.Aim: to study the secretion of GLP-1, GIP, insulin and glucagon and their relationship
Ivan Ivanovich Dedov   +3 more
doaj   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

open access: yesAndrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin   +3 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons [PDF]

open access: yesEndocrinology and Metabolism
Background Glucagon-like peptide-1 (GLP-1) is an incretin known for its anti-obesity effects, and several effective drugs targeting GLP-1 receptors (GLP-1Rs) have recently been developed to treat obesity.
Sujin Yoo   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy